The clinical performance of acyl-CoA oxidase deficiency is complex and often involves multiple systemic strain. Early identification and normalisation of the disease are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological evaluation.
The platform can assist in linking a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of acyl-CoA oxidase deficiency requires individualized development, usually including multidimensional management, such as drug therapy, rehabilitation, regular follow-up. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, significant improvements have been made in many previously difficult to treat genetic metabolic disorders.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of acyl-CoA oxidase deficiency. The platform serves a team of domestic and foreign experts in the field of genetic metabolism linked to the China International Medical Service System, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.